NDAORALTABLET
Approved
Jun 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
STALEVO 50 (carbidopa, levodopa, and entacapone) by Orion Pharma is catechol o-methyltransferase inhibitors [moa]. Approved for catechol-o-methyltransferase inhibitor [epc]. First approved in 2003.
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STALEVO 50 is an oral tablet combining carbidopa, levodopa, and entacapone for Parkinson's disease management. It works by inhibiting catechol O-methyltransferase (COMT) to extend levodopa availability and reduce motor fluctuations in patients with advanced disease. The fixed-dose combination optimizes dopamine replacement therapy in a single convenient tablet.
$0.040BPart D
LOE ApproachingDeclining
Modest spending ($40K) with minimal claim volume signals a niche product with a contracting commercial team and limited growth opportunities.
Mechanism of Action
Catechol O-Methyltransferase Inhibitors
Pharmacologic Class:
Catechol-O-Methyltransferase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on STALEVO 50 offers limited career momentum given its LOE-approaching lifecycle, minimal spending ($40K), and contracting claim base (39). This role suits professionals focused on defensive market management, patient access optimization, or transition planning rather than growth-oriented advancement.
Brand Manager
Worked on STALEVO 50 at Orion Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.